Vistin Pharma ASA: Volume of oil derivative contracts reduced
Oslo, Norway, 14 November 2019Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN), announces that the company has closed the derivative contract for 15,000 metric tons (MT) of the spread between ICE low sulphur gasoil and Sing380 expiring in December 2019. The position was closed at USD 364.25/MT, and resulted in a realised gain of approximately NOK 2.6 million. The spread at the contract date and 30 September 2019 was USD 345.10/MT and USD 352.80/MT respectively. Following this transaction Vistin Pharma has a total contract volume of 135,000MT outstanding. As previously communicated, any reduction in the volumes outstanding will be subsequently announced. *****For further information, please contact:Gunnar Manum
+47 95 17 91 90
firstname.lastname@example.orgThis information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.About Vistin Pharma | www.vistin.comVistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.